Genes involved in stress response influence lithium efficacy in bipolar patients

Szczepankiewicz, Aleksandra; Narożna, Beata; Rybakowski, Janusz; Kliwicki, Sebastian; Czerski, Piotr M.; Dmitrzak‐Węglarz, Monika; Skibińska, Maria; Twarowska-Hauser, Joanna; Pawlak, Joanna

doi:10.1111/bdi.12639

Cited by 13 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For coping, functions relating to behaviour were identified for six of the 11 genes: GABARAP (Hui et al., 2019), NDM (Costilla et al., 2020), OAZ1 (Fiori et al., 2012), RPS15A (Park et al., 2011), SPARCL1 (Seddighi et al., 2018) and VAMP2 ( Zhang et al., 2021). For cortisol, functions relating to behaviour were identified for five of the 14 genes: CEBPA (Chen et al., 2020), COA3 (Liu et al., 2021), DUSP1 (Horita et al., 2010; Jefsen et al., 2021; Juszczak & Stankiewicz, 2018; Szczepankiewicz et al., 2018; Takemoto et al., 2020; Zhao et al., 2017), HNRNPH1 (Gillentine et al., 2021) and RACK1 (Birikh et al., 2003; Corcoran et al., 2015; McGough et al., 2004; Neasta et al., 2012). The majority of the genes were associated with phenotypes observed in humans and mice such as social behaviour ( GABARAP ), autism spectrum disorder ( NDM ), suicide ( OAZ1 ), Alzheimer's disease ( SPRCL1 ), stress‐induced anxiety and depression ( COA3 , DUSP1 , VAMP2 ), neurodevelopmental disorders ( HNRNPH1 ), neuroinflammatory disease ( CEPBA ), fear‐induced behaviours ( RPS15A , RACK1 ), and alcohol and cocaine addiction ( RACK1 ).…”

Section: Discussionmentioning

confidence: 99%

Integrative genomics analysis highlights functionally relevant genes for equine behaviour

et al. 2023

View full text Add to dashboard Cite

Thoroughbred horses are bred for competitive racing and undergo intense training regimes, with the maintenance of physical soundness and desirable behavioural characteristics critical to the longevity of a racing career. Horses that do not easily adapt to a high-pressure training environment may have extended periods out of training to allow them to mature/settle into the training schedule, resulting in a delay in racing. Furthermore, unsuitable temperament is responsible for >6% of Thoroughbred horses discontinuing a racing career (Thomson et al., 2014). Behaviour traits therefore have animal welfare and economic implications, and may also impact on handler and rider safety.For horses entering an exercise training programme, behavioural plasticity enables adaptation to an unnatural environment (McBride & Mills, 2012) with reduced stimulation of the acute stress response. Acute stress responses are normally evolved processes that are protective whereas chronic over-activity of the stress system increases the risk of disease (McEwen, 2000).

show abstract

Section: Discussionmentioning

confidence: 99%

Integrative genomics analysis highlights functionally relevant genes for equine behaviour

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[ 16 ] First, recent studies have reported an association of FKBP5 SNPs with treatment response in affective disorders. One study of 93 patients with bipolar disorder reported that SNPs rs1360789, rs9296158, and rs7748266, were associated with lithium response, [ 41 ] whereas the TT genotype of rs1360789 was shown to be associated the response to antidepressant treatments in a STAR∗D cohort. [ 42 ] Secondly, some variants of the FKBP5 gene were also shown to be associated with the susceptibility for depression.…”

Section: Discussionmentioning

confidence: 99%

Lack of association of FKBP5 SNPs and haplotypes with susceptibility and treatment response phenotypes in Han Chinese with major depressive disorder

Yang

Shen

et al. 2021

Medicine

View full text Add to dashboard Cite

The identification of single-nucleotide polymorphisms (SNPs) in genes putatively related to pathophysiological processes in major depressive disorder (MDD) might improve both diagnosis and personalized treatment strategies eventually leading to more effective interventions. Considering the important role of the glucocorticoid receptor and the related FK506 binding protein 51 (FKBP51) in the pathophysiology of MDD, we aimed to investigate putative associations between variants of FKBP5 , the coding gene of FKBP51, with antidepressant treatment resistance and MDD susceptibility. Nine common SNPs of the FKBP5 gene prioritized based on location and, putative or known functions were genotyped in Han Chinese population, including MDD patients with or without antidepressant-treatment resistance and healthy controls. Associations of FKBP5 SNPs with MDD susceptibility and treatment response were examined in the whole group of MDD patients, as well as in subgroups stratified by antidepressant treatment resistance, compared with healthy controls. In total, 181 Han Chinese patients with MDD and 80 healthy controls were recruited. No significant SNP or haplotype associations were observed in the whole patient group. There were nominal significant differences both for the haplotype block with SNPs in strong LD ( r 2 > 0.8, P = .040) and haplotype block with SNPs in moderate LD ( r 2 > 0.1, P = .017) between the haplotype distributions of patients with antidepressant treatment resistance (n = 81) and healthy controls, but both significances did not survive multiple testing correction. Furthermore, no specific haplotype could be observed causing a significant difference in any combination between all comparisons. No associations were observed of FKBP5 variants with MDD or antidepressant treatment response. The lack of associations might be due to the relatively small sample size of this study (power ranged from 0.100 to 0.752). A follow-up study will need larger, better phenotyped, and more homogeneous samples to draw a definitive conclusion regarding the involvement of this gene in MDD.

show abstract

“…They have been those connected with neurotransmitters—serotonin transporter, dopamine D1 receptor ( DRD1 ) genes, second messengers (inositol polyphosphate 1‐phosphatase, CREB1 genes), glycogen synthase kinase 3‐β ( GSK‐3β ) gene, brain‐derived neurotrophic factor ( BDNF ) gene, glucocorticoid receptor ( NR3C1 ) gene, in circadian rhythms ( Rev‐Erba‐α gene), and genes located on chromosome 22q11‐13 (breakpoint cluster region— BCR , X‐box binding protein 1— XBP1 , and the calcium channel gamma‐2 subunit— CACNG2 ) genes (Rybakowski, 2013). Related to the role of stress factors, we found an association between prophylactic lithium efficacy and the genes connected with stress axis such as glucocorticoid receptor ( NR3C1 ) gene) and FKBP5 gene (Szczepankiewicz et al, 2018; Szczepankiewicz, Rybakowski, Suwalska, & Hauser, 2011).…”

Section: Personalized Medicine and Lithium Prophylaxis: Biological Factorsmentioning

confidence: 99%

Lithium treatment in the era of personalized medicine

Rybakowski

2020

Drug Development Research

Self Cite

View full text Add to dashboard Cite

In 1949, an Australian psychiatrist, John Cade, reported on the antimanic efficacy of lithium carbonate, which is regarded as an introduction of lithium into contemporary psychiatry. Since the 1960s, lithium has been a precursor of mood stabilizers and has become first‐choice drug for the prevention of affective episodes in mood disorders. For nearly four decades, lithium has also been used for the augmentation of antidepressant drugs in treatment‐resistant depression. The knowledge of clinical and biological factors connected with the capability of long‐term lithium treatment to prevent manic and depressive recurrences makes an important element of the personalized medicine of mood disorders. Excellent prophylactic lithium responders can be characterized by distinct mood episodes, with full remissions between them, the absence of other psychiatric morbidity, and the family history of bipolar illness. In recent years, many other clinical and biological factors connected with such a response have been identified, helping to select the best candidates for lithium prophylaxis. The antisuicidal effect of lithium during its long‐term administration has been demonstrated and should also be taken into account as the element of personalized medicine for the pharmacological prophylaxis of patients with mood disorders. Several studies pertaining to personalized medicine were also dedicated to lithium treatment of acute mood episodes. Lithium still has a value in the treatment of mania and bipolar depression. However, it seems that the more important indication would be the augmentation of antidepressant drugs in treatment‐resistant depression. The factors connected with the efficacy of lithium in these conditions are reviewed.

show abstract

Genes involved in stress response influence lithium efficacy in bipolar patients

Abstract: The response to lithium may depend on the variants of genes regulating the HPA axis and stressful life events in bipolar patients.

Cited by 13 publications

References 42 publications

Integrative genomics analysis highlights functionally relevant genes for equine behaviour

Integrative genomics analysis highlights functionally relevant genes for equine behaviour

Lack of association of FKBP5 SNPs and haplotypes with susceptibility and treatment response phenotypes in Han Chinese with major depressive disorder

Lithium treatment in the era of personalized medicine

Contact Info

Product

Resources

About